Alfredo Addeo has noted two issues in our trial¹ of dacomitinib versus gefitinib in patients with non-small-cell lung cancer (NSCLC): the fact that we did not discuss central nervous system (CNS) penetration by dacomitinib and the similar progression-free survival in the Asian and non-Asian intention-to-treat (ITT) subpopulations.

中文翻译：

---

达科替尼在非小细胞肺癌中的临床试验：阳性试验，对临床影响不大–作者的回复

Alfredo Addeo在我们的dacomitinib与gefitinib的非小细胞肺癌（NSCLC）患者的试验¹中指出了两个问题：我们没有讨论dacomitinib对中枢神经系统（CNS）的渗透以及类似的无进展情况亚洲和非亚洲意图治疗（ITT）亚人群的生存率。